CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner

Combining immunotherapy with targeted therapy has increasingly become an appealing therapeutic paradigm for cancer treatment due to its great potential for generating durable and synergistic antitumor response. In this study, however, we unexpectedly found that two types of CpG-based tumor peptide v...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, L, Wang, Z, Liu, C, Xu, C, Mbofung, R M, McKenzie, J A, Khong, H, Hwu, P, Peng, W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509483/
https://www.ncbi.nlm.nih.gov/pubmed/28263973
http://dx.doi.org/10.1038/onc.2017.35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509483/
https://www.ncbi.nlm.nih.gov/pubmed/28263973
http://dx.doi.org/10.1038/onc.2017.35

Ejemplares similares